Barrington Research Predicts Weaker Earnings for Surmodics

Key Points

• Barrington Research has revised down its Q2 2026 earnings per share (EPS) estimates for Surmodics to $0.00, down from a previous forecast of $0.01, maintaining a "Market Perform" rating on the stock.
• Surmodics reported a quarterly EPS of $0.06 for the last quarter, surpassing the consensus estimate of ($0.21) by $0.27, indicating some positive performance despite lowered future expectations.
• Hedge funds and institutional investors continue to hold significant stakes in Surmodics, with 96.63% of the company owned by these entities, reflecting strong institutional interest despite the recent earnings forecast adjustments.

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Equities research analysts at Barrington Research lowered their Q2 2026 earnings per share (EPS) estimates for shares of Surmodics in a report released on Monday, August 11th. Barrington Research analyst M. Petusky now expects that the company will post earnings of $0.00 per share for the quarter, down from their prior forecast of $0.01. Barrington Research currently has a "Market Perform" rating on the stock. The consensus estimate for Surmodics' current full-year earnings is $0.20 per share. Barrington Research also issued estimates for Surmodics' Q3 2026 earnings at $0.00 EPS and Q4 2026 earnings at $0.06 EPS.

Separately, Needham & Company LLC reaffirmed a "hold" rating on shares of Surmodics in a report on Wednesday, April 30th.

Surmodics Price Performance

NASDAQ SRDX opened at $38.00 on Tuesday. The company has a market cap of $543.40 million, a PE ratio of -30.89 and a beta of 1.31. Surmodics has a 52 week low of $26.00 and a 52 week high of $41.29. The company has a quick ratio of 3.10, a current ratio of 3.91 and a debt-to-equity ratio of 0.27. The firm's 50-day simple moving average is $31.44 and its two-hundred day simple moving average is $30.78.

Surmodics (NASDAQ:SRDX - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.21) by $0.27. The business had revenue of $29.57 million for the quarter, compared to the consensus estimate of $28.04 million. Surmodics had a negative net margin of 14.59% and a negative return on equity of 3.04%.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its holdings in shares of Surmodics by 20.1% during the fourth quarter. JPMorgan Chase & Co. now owns 50,990 shares of the company's stock worth $2,019,000 after purchasing an additional 8,520 shares in the last quarter. Wells Fargo & Company MN grew its holdings in shares of Surmodics by 40.9% during the fourth quarter. Wells Fargo & Company MN now owns 7,032 shares of the company's stock worth $278,000 after purchasing an additional 2,041 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of Surmodics by 34.2% during the fourth quarter. Legal & General Group Plc now owns 3,452 shares of the company's stock worth $137,000 after purchasing an additional 880 shares in the last quarter. Barclays PLC grew its holdings in shares of Surmodics by 21.7% during the fourth quarter. Barclays PLC now owns 108,001 shares of the company's stock worth $4,278,000 after purchasing an additional 19,251 shares in the last quarter. Finally, Gabelli Funds LLC grew its holdings in shares of Surmodics by 3.7% during the fourth quarter. Gabelli Funds LLC now owns 339,959 shares of the company's stock worth $13,462,000 after purchasing an additional 12,250 shares in the last quarter. Hedge funds and other institutional investors own 96.63% of the company's stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.